In CML, response to treatment with tyrosine kinase inhibitors (TKI), as measured by BCR::ABL1 transcript levels is known to be the most important prognostic factor [14]. This evidence concerns the gene BCR and chronic myelogenous leukemia, BCR-ABL1 positive.